Advertisement

Upregulated expression of human cathelicidin LL-37 in hypercholesterolemia and its relationship with serum lipid levels

  • Yun-Xi Li
  • Bao-Zhen Li
  • Da-Zun Yan
Article
  • 81 Downloads

Abstract

Dyslipidemia in patients with hypercholesterolemia has been recently linked to increased human cathelicidin LL-37 (LL-37) serum concentration. We tested a hypothesis that upregulated expression of LL-37 gene in peripheral blood leucocytes is involved in dyslipidemia in patients with hypercholesteremia. Patients with hypercholesterolemia were used in the study. Expression of LL-37 and human glyceraldehyde-3-phosphate dehydrogenase in peripheral blood leucocytes were quantified by real-time RT-PCR. Serum LL-37 concentration was estimated by enzyme-linked immunosorbent assay. Serum lipid levels were assessed by absorptiometry in all cases. Patients with hypercholesterolemia as compared to control ones were characterized by (a) an up-regulation of LL-37 gene expression in peripheral blood leucocytes with parallel increase of serum LL-37 concentration and (b) an increase of serum total and low-density lipoprotein cholesterol concentrations. Patients with hypercholesterolemia after a treatment with atorvastatin calcium 20 mg daily as compared to that patients before the treatment: an down-regulation of LL-37 gene expression in peripheral blood leucocytes with parallel decrease of serum LL-37 concentration. We also found significant correlation between serum LL-37 and high-density lipoprotein cholesterol levels (r = 0.7290, P < 0.0001). The results suggest that hypercholesterolemia is associated with an increased LL-37 gene expression in peripheral blood leucocytes. The correlation between serum LL-37 and high-density lipoprotein cholesterol levels suggests that LL-37 may play a key role in regulation of cholesterol levels in hypercholesterolemia.

Keywords

Human cathelicidin LL-37 Gene expression Hypercholesteremia Blood lipid indexes 

Notes

Acknowledgements

This study was supported by the Technological Bureau of Zhongshan, Guangdong, China [Grants Number 2015B1158].

Compliance with ethical standards

Conflict of interest

All authors declare that they have no conflict of interest.

Ethical approval

Volunteer adults were recruited from Guangdong Medical University Affiliated Zhongshan Hospital with the informed consent of the individuals after permission by the ethical committees of Guangdong Medical University Affiliated Zhongshan Hospital, Zhongshan, China.

References

  1. 1.
    Sun L, Wang W, Xiao W, Yang H (2016) The roles of cathelicidin LL-37 in inflammatory Bowel disease. Inflamm Bowel Dis 22:1986–1991CrossRefPubMedGoogle Scholar
  2. 2.
    Hu Z, Murakami T, Suzuki K, Tamura H, Reich J, Kuwahara-Arai K et al (2016) Antimicrobial cathelicidin peptide LL-37 inhibits the pyroptosis of macrophages and improves the survival of polybacterial septic mice. Int Immunol 28:245–253CrossRefPubMedPubMedCentralGoogle Scholar
  3. 3.
    Le J, Dam Q, Schweizer M, Thienphrapa W, Nizet V, Sakoulas G (2016) Effects of vancomycin versus nafcillin in enhancing killing of methicillin-susceptible Staphylococcus aureus causing bacteremia by human cathelicidin LL-37. Eur J Clin Microbiol Infect Dis 35:1441–1447CrossRefPubMedPubMedCentralGoogle Scholar
  4. 4.
    Harcourt JL, McDonald M, Svoboda P, Pohl J, Tatti K, Haynes LM (2016) Human cathelicidin, LL-37, inhibits respiratory syncytial virus infection in polarized airway epithelial cells. BMC Res Notes 9:11–11CrossRefPubMedPubMedCentralGoogle Scholar
  5. 5.
    Currie SM, Gwyer Findlay E, McFarlane AJ, Fitch PM, Bottcher B, Colegrave N et al (2016) Cathelicidins have direct antiviral activity against respiratory syncytial virus in vitro and protective function in vivo in mice and humans. J Immunol 196:2699–2710CrossRefPubMedPubMedCentralGoogle Scholar
  6. 6.
    Marr AK, Cen S, Hancock RE, McMaster WR (2016) Identification of synthetic and natural host defense peptides with leishmanicidal activity. Antimicrob Agents Chemother 60:2484–2491CrossRefPubMedPubMedCentralGoogle Scholar
  7. 7.
    Ciornei CD, Tapper H, Bjartell A, Sternby NH, Bodelsson M (2006) Human antimicrobial peptide LL-37 is present in atherosclerotic plaques and induces death of vascular smooth muscle cells: a laboratory study. BMC Cardiovasc Disord 6:49–49CrossRefPubMedPubMedCentralGoogle Scholar
  8. 8.
    Edfeldt K, Agerberth B, Rottenberg ME, Gudmundsson GH, Wang XB, Mandal K et al (2006) Involvement of the antimicrobial peptide LL-37 in human atherosclerosis. Arterioscler Thromb Vasc Biol 26:1551–1557CrossRefPubMedGoogle Scholar
  9. 9.
    Soehnlein O, Wantha S, Simsekyilmaz S, Doring Y, Megens RT, Mause SF et al (2011) Neutrophil-derived cathelicidin protects from neointimal hyperplasia. Sci Transl Med 3:103ra98CrossRefPubMedPubMedCentralGoogle Scholar
  10. 10.
    Zhao H, Yan H, Yamashita S, Li W, Liu C, Chen Y et al (2012) Acute ST-segment elevation myocardial infarction is associated with decreased human antimicrobial peptide LL-37 and increased human neutrophil peptide-1 to 3 in plasma. J Atheroscler Thromb 19:357–368CrossRefPubMedGoogle Scholar
  11. 11.
    Meguro S, Tomita M, Katsuki T, Kato K, Oh H, Ainai A et al (2014) Plasma antimicrobial peptide LL-37 level is inversely associated with HDL cholesterol level in patients with type 2 diabetes mellitus. Int J Endocrinol 2014:703696–703701PubMedPubMedCentralGoogle Scholar
  12. 12.
    Li YX, Lin CQ, Shi DY, Zeng SY, Li WS (2014) Upregulated expression of human alpha-defensins 1, 2 and 3 in hypercholesteremia and its relationship with serum lipid levels. Hum Immunol 75:1104–1109CrossRefPubMedGoogle Scholar
  13. 13.
    Gonzalez-Curiel I, Castaneda-Delgado J, Lopez-Lopez N, Araujo Z, Hernandez-Pando R, Gandara-Jasso B et al (2011) Differential expression of antimicrobial peptides in active and latent tuberculosis and its relationship with diabetes mellitus. Hum Immunol 72:656–662CrossRefPubMedGoogle Scholar
  14. 14.
    Bertolini S, Cantafora A, Averna M, Cortese C, Motti C, Martini S et al (2000) Clinical expression of familial hypercholesterolemia in clusters of mutations of the LDL receptor gene that cause a receptor-defective or receptor-negative phenotype. Arterioscler Thromb Vasc Biol 20:E41–E52CrossRefPubMedGoogle Scholar
  15. 15.
    Benachour H, Zaiou M, Samara A, Herbeth B, Pfister M, Lambert D et al (2009) Association of human cathelicidin (hCAP-18/LL-37) gene expression with cardiovascular disease risk factors. Nutr Metab Cardiovasc Dis 19:720–728CrossRefPubMedGoogle Scholar
  16. 16.
    Bedi B, McNair NN, Forster I, Mead JR (2014) IL-18 cytokine levels modulate innate immune responses and cryptosporidiosis in mice. J Eukaryot Microbiol 62:44–50CrossRefPubMedGoogle Scholar
  17. 17.
    Lenglet S, Quercioli A, Fabre M, Galan K, Pelli G, Nencioni A et al (2014) Statin treatment is associated with reduction in serum levels of receptor activator of NF-kappa B ligand and neutrophil activation in patients with severe carotid stenosis. Mediators Inflamm 2014:720987–720987CrossRefPubMedPubMedCentralGoogle Scholar
  18. 18.
    Concha MI, Smith VJ, Castro K, Bastias A, Romero A, Amthauer RJ (2004) Apolipoproteins A-I and A-II are potentially important effectors of innate immunity in the teleost fish Cyprinus carpio. Eur J Biochem 271:2984–2990CrossRefPubMedGoogle Scholar
  19. 19.
    Hoang-Yen DT, Hoang-Ngoc DT, Mattai SA, Sallam T, Ortiz C, Lee EC et al (2016) Cathelicidin suppresses lipid accumulation and hepatic steatosis by inhibition of the CD36 receptor. Int J Obes 40:1424–1434CrossRefGoogle Scholar
  20. 20.
    Ma W, Shen D, Liu J, Pan J, Yu L, Shi W et al (2016) Statin function as an anti-inflammation therapy for depression in patients with coronary artery disease by downregulating interleukin-1 beta. J Cardiovasc Pharmacol 67:129–135CrossRefPubMedGoogle Scholar
  21. 21.
    Schrumpf JA, van Sterkenburg MA, Verhoosel RM, Zuyderduyn S, Hiemstra PS (2012) Interleukin 13 exposure enhances vitamin D- mediated expression of the human cathelicidin antimicrobial peptide 18/LL-37 in bronchial epithelial cells. Infect Immun 80:4485–4494CrossRefPubMedPubMedCentralGoogle Scholar
  22. 22.
    Lee JS, Rosengart MR, Kondragunta V, Zhang Y, McMurray J, Branch RA et al (2007) Inverse association of plasma IL-13 and inflammatory chemokines with lung function impairment in stable COPD: a cross-sectional cohort study. Respir Res 8:64–64CrossRefPubMedPubMedCentralGoogle Scholar
  23. 23.
    Zhang M, Lu Y, Liu X, Tie Y (2016) Relationship between xspI site polymorphisms of LDL-R gene and serum IL-2 and IL-10 in patients with hypercholesterolemia. J Clin Lab Anal 30:1122–1127CrossRefPubMedGoogle Scholar
  24. 24.
    Dixon BM, Barker T, McKinnon T, Cuomo J, Frei B, Borregaard N et al (2012) Positive correlation between circulating cathelicidin antimicrobial peptide (hCAP18/LL-37) and 25-hydroxyvitamin D levels in healthy adults. BMC Res Notes 5:575–579CrossRefPubMedPubMedCentralGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2018

Authors and Affiliations

  1. 1.Department of Clinical LaboratoryGuangdong Medical University Affiliated Zhongshan HospitalXiaolanChina
  2. 2.Department of Clinical LaboratoryGuangdong Medical UniversityZhanjiangChina

Personalised recommendations